



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 07/13/2020 06:47
Last Report Issued 03/05/2020 11:23

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 0962SP
Patient ID 0962SP
Chain 20000387
Age Not Given DOB Not Given
Gender Not Given
Workorder 20000387
Received 03/05/2020 11:18

Sample ID 20000387-001
Matrix Serum or Plasma
Patient Name 0962SP
Patient ID 0962SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

0962SP Cannabidiol, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Table row: Cannabidiol, None Detected, ng/mL, 0.10

Synonym(s): CBD

Mean peak CBD plasma concentrations at 3-4 hours
post-dose with Sativex® at a low dose
(5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol)
were 1.6 +/- 0.4 ng/mL and at a high dose
(16 mg of Delta-9 THC and 15 mg of Cannabidiol)
were 6.7 +/- 2.0 ng/mL.

Following high dose 400 and 800 mg oral synthetic CBD
in corn oil administration, mean peak CBD plasma
concentrations occurred within 1.5-3 hours post-dose
and were 181.2 +/- 39.8 and 221.1 +/- 35.6 ng/mL,
respectively.

The ratio of blood to serum or plasma concentration is
unknown for this analyte.

Known Interferences: Excessive amounts of oleamide from
plastic tubes.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US
Food and Drug Administration.